Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality...

Area of Science:

• Oncology
• Pharmacovigilance
• Drug Safety

Background:

• Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) are standard treatments for advanced non-small cell lung cancer (NSCLC) with ALK rearrangements.
• Understanding the adverse event (AE) profiles of ALK-TKIs is crucial for patient safety and effective treatment strategies.

Purpose of the Study:

• To investigate ALK-TKI-associated adverse events (AEs), specifically identifying hepatotoxicity signals and previously undocumented safety concerns.
• To analyze AE reporting data to inform clinical monitoring and potential drug label updates.

Main Methods:

• Disproportionality analysis of 56,864 reports from the FDA Adverse Event Reporting System (FAERS) database.
• Systematic classification of AEs using the Medical Dictionary for Regulatory Activities (MedDRA).
• Comparison of AE profiles across different ALK-TKIs (crizotinib, ceritinib, loratinib, alectinib).

Main Results:

• Crizotinib showed a stronger signal for eye disorders; ceritinib for gastrointestinal disorders; loratinib for metabolism and nutrition disorders.
• Several previously undocumented AEs were identified, including pericardial effusion, elevated C-reactive protein, hemolytic anemia, hemoptysis, and decreased hemoglobin.
• Crizotinib, ceritinib, and alectinib were significantly associated with hepatotoxicity, indicated by elevated liver enzymes (ALT, AST).

Conclusions:

• Vigilant monitoring for unlabeled AEs is necessary for patients receiving ALK-TKIs.
• The findings suggest potential label updates are warranted, particularly regarding the hepatotoxicity risks of crizotinib, ceritinib, and alectinib.
• This research contributes to a better understanding of ALK-TKI safety profiles in real-world settings.